Cresco Labs Q2 revenue beats estimates

Cresco Labs

07/08/2025 11:38

Overview

Cresco Labs Q2 revenue of $164 mln beats analyst expectations

Company reports Q2 net loss of $14 mln due to impairment charges

Co signs $325 mln term loan commitment to refinance debt

Outlook

Company sees M&A opportunities in productive states

Cresco Labs plans to invest in sustainable growth opportunities

Company aims to be a partner of choice as industry consolidates

Result Drivers

DEBT REFINANCING - Cresco Labs signed a $325 mln term loan commitment to refinance debt, enhancing financial flexibility

MARKET SHARE - Co maintained No. 1 share position in multiple billion dollar markets

IMPAIRMENT CHARGES - Net loss includes $9 mln non-cash impairment charges related to California assets held for sale

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$164 mln
$162.70 mln (7 Analysts)
Q2 Net Income
-$14 mln
Q2 Adjusted EBITDA
$41 mln
Q2 Adjusted Gross Margin
50.6%
Q2 Gross Profit
$83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Cresco Labs Inc is C$2.00, about 53.5% above its August 6 closing price of C$0.93

Press Release: ID:nBw4wSGRNa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)